Organ-on-a-chip Market Research Report: By Organ Type (Lung-on-Chip, Heart-on-Chip, Liver-on-Chip, Intestine-on-Chip, Kidney-on-Chip, Human-on-Chip), By Application (Drug Discovery, Toxicology Research, Others) and By End-User (Pharmaceutical Companies, Research Organizations, Others) – Forecast to 2030
ID: MRFR/HC/7026-HCR | February 2021 | Region: Global | 120 Pages
Table of Contents
1. REPORT PROLOGUE
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Primary Research
3.3. Secondary Research
3.4. Market Size Estimation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Porter’s Five Forces Analysis
5.1.1. Bargaining Power of Suppliers
5.1.2. Bargaining Power of Buyers
5.1.3. Threat of New Entrants
5.1.4. Threat of Substitutes
5.1.5. Intensity of Rivalry
5.2. Value Chain Analysis
 
6. GLOBAL ORGAN-ON-A-CHIP MARKET, BY ORGAN TYPE
6.1. Overview
6.2. Lung-on-Chip
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.3. Heart-on-Chip
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.4. Liver-on-Chip
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.5. Intestine-on-Chip
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.6. Kidney-on-Chip
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.7. Skin-on-Chip
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.8. Blood-Brain Barrier-on-Chip
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.9. Human-on-Chip
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.10. Others
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7. GLOBAL ORGAN-ON-A-CHIP MARKET, BY APPLICATION
7.1. Overview
7.2. Drug Discovery
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.3. Toxicology Research
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.4. Others
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8. GLOBAL ORGAN-ON-A-CHIP MARKET, BY ENDUSER
8.1. Overview
8.2. Pharmaceutical Companies
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8.3. Research Organizations
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8.4. Others
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
9. GLOBAL ORGAN-ON-A-CHIP MARKET, BY REGION
9.1. Overview
9.2. Americas
9.2.1. North America
9.2.1.1. US
9.2.1.2. Canada
9.2.2. Latin America
9.3. Europe
9.3.1. Western Europe
9.3.1.1. Germany
9.3.1.2. France
9.3.1.3. Italy
9.3.1.4. Spain
9.3.1.5. UK
9.3.1.6. Rest of Western Europe
9.3.2. Eastern Europe
9.4. Asia-Pacific
9.4.1. Japan
9.4.2. China
9.4.3. India
9.4.4. Australia
9.4.5. South Korea
9.4.6. Rest of Asia-Pacific
9.5. Middle East & Africa
9.5.1. Middle East
9.5.2. Africa
10. COMPANY LANDSCAPE
10.1. Overview
10.2. Competitive Analysis
10.3. Market Share Analysis
10.4. Major Growth Strategy in the Global Organ-on-a-Chip Market
10.5. Competitive Benchmarking
10.6. Leading Players in terms of Number of Developments in the Global Organ-on-a-Chip Market
10.7. Key Developments and Growth Strategies
10.7.1. Product Launch
10.7.2. Merger & Acquisitions
10.7.3. Joint Ventures
10.8. Major Players Financial Matrix & Market Ratio
10.8.1. Sales & Operating Income 2020
10.8.2. Major Players R&D Expenditure 2020
10.9. Major Players Capital Market Ratio
11. COMPANY PROFILES
11.1. CN Bio Innovations Limited
11.1.1. Company Overview
11.1.2. Financial Overview
11.1.3. Product Offered
11.1.4. Key Developments
11.1.5. SWOT Analysis
11.1.6. Key Strategies
11.2. Emulate
11.2.1. Company Overview
11.2.2. Financial Overview
11.2.3. Product Offered
11.2.4. Key Developments
11.2.5. SWOT Analysis
11.2.6. Key Strategies
11.3. TissUse
11.3.1. Company Overview
11.3.2. Financial Overview
11.3.3. Product Offered
11.3.4. Key Developments
11.3.5. SWOT Analysis
11.3.6. Key Strategies
11.4. Mimetas
11.4.1. Company Overview
11.4.2. Financial Overview
11.4.3. Product Offered
11.4.4. Key Developments
11.4.5. SWOT Analysis
11.4.6. Key Strategies
11.5. Hµrel
11.5.1. Company Overview
11.5.2. Financial Overview
11.5.3. Product Offered
11.5.4. Key Developments
11.5.5. SWOT Analysis
11.5.6. Key Strategies
11.6. Nortis
11.6.1. Company Overview
11.6.2. Financial Overview
11.6.3. Product Offered
11.6.4. Key Developments
11.6.5. SWOT Analysis
11.6.6. Key Strategies
11.7. Insphero
11.7.1. Company Overview
11.7.2. Financial Overview
11.7.3. Product Offered
11.7.4. Key Developments
11.7.5. SWOT Analysis
11.7.6. Key Strategies
11.8. Tara Biosystems
11.8.1. Company Overview
11.8.2. Financial Overview
11.8.3. Product Offered
11.8.4. Key Developments
11.8.5. SWOT Analysis
11.8.6. Key Strategies
11.9. AxoSim Technologies LLC
11.9.1. Company Overview
11.9.2. Financial Overview
11.9.3. Product Offered
11.9.4. Key Developments
11.9.5. SWOT Analysis
11.9.6. Key Strategies
11.10. Organovo
11.10.1. Company Overview
11.10.2. Financial Overview
11.10.3. Product Offered
11.10.4. Key Developments
11.10.5. SWOT Analysis
11.10.6. Key Strategies
11.11. BioIVT
11.11.1. Company Overview
11.11.2. Financial Overview
11.11.3. Product Offered
11.11.4. Key Developments
11.11.5. SWOT Analysis
11.11.6. Key Strategies
11.12. HemoShear
11.12.1. Company Overview
11.12.2. Financial Overview
11.12.3. Product Offered
11.12.4. Key Developments
11.12.5. SWOT Analysis
11.12.6. Key Strategies
12. APPENDIX
12.1. References
12.2. Related Reports 
LIST OF TABLES
TABLE 1 GLOBAL ORGAN-ON-A-CHIP MARKET SYNOPSIS, 2020-2027
TABLE 2 GLOBAL ORGAN-ON-A-CHIP MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)
TABLE 3 GLOBAL ORGAN-ON-A-CHIP MARKET, BY ORGAN TYPE, 2020-2027 (USD MILLION)
TABLE 4 GLOBAL ORGAN-ON-A-CHIP MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 5 GLOBAL ORGAN-ON-A-CHIP MARKET, BY ENDUSER, 2020-2027 (USD MILLION)
TABLE 6 GLOBAL ORGAN-ON-A-CHIP MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 7 NORTH AMERICA: ORGAN-ON-A-CHIP MARKET, BY ORGAN TYPE, 2020-2027 (USD MILLION)
TABLE 8 NORTH AMERICA: ORGAN-ON-A-CHIP MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 9 NORTH AMERICA: ORGAN-ON-A-CHIP MARKET, BY ENDUSER, 2020-2027 (USD MILLION)
TABLE 10 US: ORGAN-ON-A-CHIP MARKET, BY ORGAN TYPE, 2020-2027 (USD MILLION)
TABLE 11 US: ORGAN-ON-A-CHIP MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 12 US: ORGAN-ON-A-CHIP MARKET, BY ENDUSER, 2020-2027 (USD MILLION)
TABLE 13 CANADA: ORGAN-ON-A-CHIP MARKET, BY ORGAN TYPE, 2020-2027 (USD MILLION)
TABLE 14 CANADA: ORGAN-ON-A-CHIP MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 15 CANADA: ORGAN-ON-A-CHIP MARKET, BY ENDUSER, 2020-2027 (USD MILLION)
TABLE 16 LATIN AMERICA: ORGAN-ON-A-CHIP MARKET, BY ORGAN TYPE, 2020-2027 (USD MILLION)
TABLE 17 LATIN AMERICA: ORGAN-ON-A-CHIP MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 18 LATIN AMERICA: ORGAN-ON-A-CHIP MARKET, BY ENDUSER, 2020-2027 (USD MILLION)
TABLE 19 EUROPE: ORGAN-ON-A-CHIP MARKET, BY ORGAN TYPE, 2020-2027 (USD MILLION)
TABLE 20 EUROPE: ORGAN-ON-A-CHIP MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 21 EUROPE: ORGAN-ON-A-CHIP MARKET, BY ENDUSER, 2020-2027 (USD MILLION)
TABLE 22 WESTERN EUROPE: ORGAN-ON-A-CHIP MARKET, BY ORGAN TYPE, 2020-2027 (USD MILLION)
TABLE 23 WESTERN EUROPE: ORGAN-ON-A-CHIP MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 24 WESTERN EUROPE: ORGAN-ON-A-CHIP MARKET, BY ENDUSER, 2020-2027 (USD MILLION)
TABLE 25 EASTERN EUROPE: ORGAN-ON-A-CHIP MARKET, BY ORGAN TYPE, 2020-2027 (USD MILLION)
TABLE 26 EASTERN EUROPE: ORGAN-ON-A-CHIP MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 27 EASTERN EUROPE: ORGAN-ON-A-CHIP MARKET, BY ENDUSER, 2020-2027 (USD MILLION)
TABLE 28 ASIA-PACIFIC: ORGAN-ON-A-CHIP MARKET, BY ORGAN TYPE, 2020-2027 (USD MILLION)
TABLE 29 ASIA-PACIFIC: ORGAN-ON-A-CHIP MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 30 ASIA-PACIFIC: ORGAN-ON-A-CHIP MARKET, BY ENDUSER, 2020-2027 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA: ORGAN-ON-A-CHIP MARKET, BY ORGAN TYPE, 2020-2027 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA: ORGAN-ON-A-CHIP MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA: ORGAN-ON-A-CHIP MARKET, BY ENDUSER, 2020-2027 (USD MILLION)
 
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL ORGAN-ON-A-CHIP MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL ORGAN-ON-A-CHIP MARKET
FIGURE 4 GLOBAL ORGAN-ON-A-CHIP MARKET SHARE, BY ORGAN TYPE, 2020 (%)
FIGURE 5 GLOBAL ORGAN-ON-A-CHIP MARKET SHARE, BY APPLICATION, 2020 (%)
FIGURE 6 GLOBAL ORGAN-ON-A-CHIP MARKET SHARE BY ENDUSER,2020 (%)
FIGURE 6 GLOBAL ORGAN-ON-A-CHIP MARKET SHARE, BY REGION, 2020 (%)
FIGURE 7 AMERICAS: ORGAN-ON-A-CHIP MARKET SHARE BY REGION, 2020 (%)
FIGURE 7 NORTH AMERICA: ORGAN-ON-A-CHIP MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 8 EUROPE: ORGAN-ON-A-CHIP MARKET SHARE, BY REGION, 2020 (%)
FIGURE 9 WESTERN EUROPE: ORGAN-ON-A-CHIP MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 10 ASIA-PACIFIC: ORGAN-ON-A-CHIP MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 11 MIDDLE EAST & AFRICA: ORGAN-ON-A-CHIP MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 12 GLOBAL ORGAN-ON-A-CHIP MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
FIGURE 13 CN BIO INNOVATIONS LIMITED.: KEY FINANCIALS
FIGURE 14 CN BIO INNOVATIONS LIMITED: SEGMENTAL REVENUE
FIGURE 15 CN BIO INNOVATIONS LIMITED: REGIONAL REVENUE
FIGURE 16 EMULATE: KEY FINANCIALS
FIGURE 17 EMULATE: SEGMENTAL REVENUE
FIGURE 18 EMULATE: REGIONAL REVENUE
FIGURE 19 TISSUSE: KEY FINANCIALS
FIGURE 20 TISSUSE: SEGMENTAL REVENUE
FIGURE 21 TISSUSE: REGIONAL REVENUE
FIGURE 22 MIMETAS: KEY FINANCIALS
FIGURE 23 MIMETAS: SEGMENTAL REVENUE
FIGURE 24 MIMETAS: REGIONAL REVENUE
FIGURE 25 HµREL: KEY FINANCIALS
FIGURE 26 HµREL: SEGMENTAL REVENUE
FIGURE 27 HµREL: REGIONAL REVENUE
FIGURE 28 NORTIS: KEY FINANCIALS
FIGURE 29 NORTIS: SEGMENTAL REVENUE
FIGURE 30 NORTIS: REGIONAL REVENUE
FIGURE 31 TARA BIOSYSTEMS: KEY FINANCIALS
FIGURE 32 TARA BIOSYSTEMS: SEGMENTAL REVENUE
FIGURE 33 TARA BIOSYSTEMS: REGIONAL REVENUE
FIGURE 34 INSPHERO: KEY FINANCIALS
FIGURE 35 INSPHERO: SEGMENTAL REVENUE
FIGURE 36 INSPHERO: REGIONAL REVENUE
FIGURE 37 AXOSIM TECHNOLOGIES LLC: KEY FINANCIALS
FIGURE 38 AXOSIM TECHNOLOGIES LLC: SEGMENTAL REVENUE
FIGURE 39 AXOSIM TECHNOLOGIES LLC: REGIONAL REVENUE
FIGURE 40 ASCENDANCE: KEY FINANCIALS
FIGURE 41 ASCENDANCE: SEGMENTAL REVENUE
FIGURE 42 ASCENDANCE: REGIONAL REVENUE
FIGURE 43 HEMOSHEAR: KEY FINANCIALS
FIGURE 44 HEMOSHEAR: SEGMENTAL REVENUE
FIGURE 45 HEMOSHEAR: REGIONAL REVENUE
Organ-on-a-chip Market
The Organ-On-a-Chip Market (OOC) is expected to hold a value of USD 115.9 Million by 2030 at a CAGR of 11.80%.
$115.9 Million
Market Size
11.80%
CAGR
North America
Dominating Region
2022-2030
Forecast Period
Segmentation
Key Players
- CN Bio Innovations Limited (UK)
- Emulate Inc. (US)
- TissUse GmbH (Germany)
- MIMETAS BV (Netherlands)
- Hµrel Corporation
- Nortis Inc. (US)
- InSphero (Switzerland)
- TARA Biosystems Inc. (US)
- Axosim (US)
- Organovo Holdings Inc. (US)
- BioIVT (US)
- HemoShear Therapeutics
- LLC (US)
Drivers
- Increasing investment by major companies in organ-on-a-chip research & development
- The growing demand for drug screening with organs-on-a-chips
Organ-On-a-Chip Market Overview
Organ-On-a-Chip Market (OOC) is expected to hold a value of USD 115.9 Million by 2030 at a CAGR of 11.80%. Organs-on-chips (OOCs) are small plastic devices with biocompatible microfluidic chambers, which contain multiple live human cells in a 3D culture that simulate vital physiological functions of body organs. These cells are placed in an environment that artificially replicates aspects of the human body, such as morphology, movement, flow, electrical stimuli, and liquid gradients.
There has been an increase in the number of collaborative sales agreements between pharmaceutical companies and university spin-offs and the entry of new advanced models of OOCs into the market. The anticipated launch of advanced organ-specific models and human-on-chip models is expected to increase the growth rate of this Organ-On-a-Chip market in the future further.
The small size of the market is mainly because OOCs have not yet been fully commercialized. They are still in the research and development phase and are being used by a limited number of end-users.
Organ-On-a-Chip Market Influencer
The ability of OOC models to reduce drug development costs drastically and grants by government and non-government entities are the major factors influencing the market growth. It is expected to rise at this high CAGR due to an increase in the number of collaborative sales agreements between the pharmaceutical companies and university spin-offs and the entry of new advanced models of OOCs into the market. The anticipated launch of advanced organ-specific models and human-on-chip models is expected to further increase the growth rate of this Organ On a Chip market in the future. Grants by government and non-government entities have been the key drivers for the global OOC industry to date. The ability of OOC models to cut drug development costs drastically will be a key market driver in the future.
Moreover, improved drug screening methodologies increased R&D by major players, strategic initiatives and increasing technological advancements are also anticipated to fuel the market growth during the forecast period.
Organ-On-a-Chip Market Drivers
- Increasing investment by major companies in organ-on-a-chip research & development (r&d)
- The growing demand for drug screening with organs-on-a-chips
- Increasing focus of organ-on-chips companies on an integrated approach, OOCs for human disease models, personalized drug tests, and regulatory status of tests using MOOCs
- Increasing government initiatives and government funding for R&D of OOCs: Major companies such as Mimetas and InSphero have been collaborating with the government agencies and universities in the US and Europe for the development of novel and effective OOCs. For instance, in 2018, InSphero received USD 10 million government funding for the R&D of said OOC models.
Market Restraints
- Stringent government regulations for drug approvals
- The complexity of OOC models
Organ-On-a-Chip Market Segmentation
By Organ Type
- Lung-on-Chip: It is the largest segment in the Organ On a Chip market and had a share of approximately 20% in 2018. Lung on a chip is a complex three-dimensional model of a living, breathing human lung on a microchip.
- Heart-on-Chip: It is a device that is used to produce cardiac tissues in three-dimension models. This device is used to study cardiac drug development and cardiotoxicity testing for personalized medicine and damaged heart tissue regeneration.
- Liver-on-Chip: This chip generates biochemical and metabolic information and shows the functioning of the liver. Fluorescent biosensor cells in the chip show changes in liver cell functions including cell death or damage to free radicals. The significant applications of liver on chips are to test general toxicity, mechanistic toxicity, and nutrient metabolism.
- Intestine-on-Chip: These chips are used to study intestinal physiology and pathophysiology of human intestines. It is also used as a research tool for applications such as studies of metabolism, nutrition, infection, and drug pharmacokinetics, as well as personalized medicine.
- Kidney-on-Chip: Kidney on chips constitute organ-chips, cells, and reagents. These chips are used in testing general toxicity, mechanistic toxicity, and drug transportation in kidneys.
- Skin-on-Chip: These chips are used in stimulating inflammation, edema, and drug-based skin disease treatments. Skin on chips is used to culture skin tissues within a microfluidic system that controls many physical and biochemical parameters of the human skin.
- Blood-Brain Barrier-on-Chip: These chips are used in maintaining brain homeostasis, immunocytochemistry for analyzing cell morphology and protein marker expression, permeability assay, and calcium imaging for studying neuronal functioning of the brain.
- Human-on-Chip: These are microfluidic devices that are lined with living human cells and are used for drug development, disease modeling, and personalized medicine. These chips are also used to predict human pharmacokinetic and pharmacodynamic responses of drugs on the human body.
By Application
- Drug Discovery: The largest segment in the Organ on a Chip market, owing to a large number of pharmaceutical companies are focusing on drug testing through organ-on-chip models.
- Toxicology Research: It is the second-largest segment in the Organ on a Chip market owing to major universities and research centers are focusing on the application of OOCs in drug toxicology testing, which is a much more advanced model compared to other drug toxicology testing methods.
- Others: Other applications of OOCs include the food & beverage and cosmetic industries
By End-User
- Pharmaceutical Companies: It is the largest segment owing to the rise in the number of pharmaceutical companies using OOCs for their r&d, drug toxicity, and efficacy testing.
- Research Organizations: It is the second-largest segment in the Organ on a Chip market owing to major universities, research organizations, non-profit research centers that are focusing on the application of OOCs in drug toxicology testing. For instance, the Wyss Institute received almost USD 5.6 million in grant money from the US FDA to use its organ-on-chip technology to test humans in 2017.
- Others: Includes small clinics and institutes and individual researchers that are working on r&d of OOCs
Organ-On-a-Chip Market By Region
- Americas: The largest regional Organ on a Chip market. Owing to the availability of a wide range of products and services offered by major players, including customized designing of new chips with specific organ arrangement and increase in toxicological testing of chemicals on the different types of organ cells.
- Europe: It is the second-largest market and expected to grow at a steady rate during the forecast period. Establishment of major OOC providers in five countries of the European Union (EU), namely the UK, Germany, France, Italy, and Spain; government initiatives and government funding to research institutes; collaborations among companies and universities to develop innovative OOCs, and a well-developed healthcare infrastructure expected to drive the market growth.
- Asia-Pacific: The fastest-growing regional Organ on a Chip market. Furthermore, the region has a supportive regulatory framework for the approval of OOCs in South Korea, Australia, Japan, and China. This factor, along with a high prevalence of chronic diseases, will drive the market during the forecast period.
- Middle East & Africa: The Middle Eastern Organ on a Chip market is expected to show more growth as compared to the African market, owing to the presence of developed countries such as Saudi Arabia and Oman in the region.
Organ-On-a-Chip Market Key Players
- CN Bio Innovations Limited (UK)
- Emulate, Inc. (US)
- TissUse GmbH (Germany)
- MIMETAS BV (Netherlands)
- Hµrel Corporation
- Nortis, Inc. (US)
- InSphero (Switzerland)
- TARA Biosystems, Inc. (US)
- Axosim (US)
- Organovo Holdings Inc. (US)
- BioIVT (US)
- HemoShear Therapeutics, LLC (US)
Report Scope:
| Report Attribute/Metric | Details |
|---|---|
| Market Size | USD 115.9 Million |
| CAGR | 11.80% 2030 |
| Base Year | 2019 |
| Forecast Period | 2020-2030 |
| Historical Data | 2018 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Organ Type, Application and End-User |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | CN Bio Innovations Limited (UK), Emulate, Inc. (US), TissUse GmbH (Germany), MIMETAS BV (Netherlands), Hµrel Corporation, Nortis, Inc. (US), InSphero (Switzerland), TARA Biosystems, Inc. (US), Axosim (US), Organovo Holdings Inc. (US), BioIVT (US), HemoShear Therapeutics, LLC (US) |
| Key Market Opportunities | Ability of OOC models to reduce drug development costs drastically and grants by government and non-government entities |
| Key Market Drivers |
|
Frequently Asked Questions (FAQ) :
Drug testing through organ-on-chip models for drug discovery and application of OOCs in drug toxicology testing as well as in the food & beverage and cosmetic industries
The valuation would be USD 115.9 million by 2030.
The restraints are stringent government rules and complex organ-on-a-chip models.
The lung-on-chip segment has the largest market valuation.
The drug discovery segment has the market upper hand.
The organ-on-a-chip market has a projected CAGR of 53% during the forecast period.
